Allegro Diagnostics, which focuses on the treatment of lung cancer and other lung diseases, has signed a license agreement with Boston University and the University of Utah Foundation for intellectual property related to its molecular testing platform - BronchoGen genomic test.
Allegro has developed a molecular testing platform that uses a genomic biomarker to detect early signs of lung cancer in current and former smokers.
The molecular testing platform uses gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer.
The company’s BronchoGen genomic test is used in combination with standard bronchoscopy for the early diagnosis of lung cancer.
Allegro Diagnostics president and CEO Mike Webb said the licensing agreement with Boston University and theUniversity of Utah Foundation helps them to achieve that goal by supporting their advancement of this platform,including the planned commercial launch of BronchoGen in the first half of 2012.